您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Felbamate-d4
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Felbamate-d4
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Felbamate-d4图片
规格:98%
分子量:242.3
包装与价格:
包装价格(元)
500ug电议
1mg电议
5mg电议

产品介绍
Felbamate-d4 (W-554-d4) 是标记为 Felbamate 的氘。
货号:ajcx22474
CAS:106817-52-1
分子式:C11H10D4N2O4
分子量:242.3
溶解度:DMF: 50 mg/ml,DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml,DMSO: 30 mg/ml,Ethanol: 1 mg/ml
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Felbamate-d4is intended for use as an internal standard for the quantification of felbamate by GC- or LC-MS. Felbamate is an inhibitor of NMDA receptors and a modulator of GABAAreceptors that also has broad-spectrum inhibitory activity against excitatory amino acid receptors.1,2,3It binds to NMDA channels with dissociation constants of approximately 200, 110, and 55 µM in the resting, activated, and desensitized states, respectively, and inhibits NMDA currents in a use-dependent manner.1Felbamate is a positive modulator of α1β2γ2S, α1β3γ2S, α2β2γ2S, and α2β3γ2Ssubunit-containing GABAAreceptors expressed inX. laevisoocytes, with negative modulation of GABAAreceptors containing the subunits α1β1, α1β3γ2L, α4β1γ2S, α4β3γ2S, and α6β1γ2S.2It inhibits seizures induced by maximal electroshock, pentylenetetrazole , and picrotoxin in mice (ED50s = 16.3, 5.51, and 5.23 mg/kg, respectively). Formulations containing felbamate have been used in the treatment of severe refractory seizures.


1.Kuo, C.-C., Lin, B.-J., Chang, H.-R., et al.Use-dependent inhibition of the N-methyl-D-aspartate currents by felbamate: a gating modifier with selective binding to the desensitized channelsMol. Pharmacol.65(2)370-380(2004) 2.Simeone, T.A., Otto, J.F., Wilcox, K.S., et al.Felbamate is a subunit selective modulator of recombinant γ-aminobutyric acid type A receptors expressed in Xenopus oocytesEur. J. Pharmacol.552(1-3)31-35(2006) 3.Domenici, M.R., Sagratella, S., Ongini, E., et al.Felbamate displays in vitro antiepileptic effects as a broad spectrum excitatory amino acid receptor antagonistEur. J. Pharmacol.271(2-3)259-263(1994)